Overview:
This open-label, 12-month clinical trial evaluated the long-term safety and efficacy of ipratropium bromide nasal spray 0.06% (84 mcg per nostril, three times daily) in patients with perennial allergic rhinitis (PAR), particularly those suffering from chronic rhinorrhea. Patients were initially treated with the full dose, with reductions allowed in the final 6 months to the lowest effective dose.
The Takeaways:
-
Ipratropium bromide nasal spray 0.06% was effective in reducing rhinorrhea and showed potential benefits for related symptoms like congestion, postnasal drip, and sneezing.
-
Physician and patient evaluations confirmed improved quality of life and reduced mucosal edema in many participants.
-
Most adverse effects (e.g., nasal dryness, epistaxis, increased rhinitis) were mild and led to discontinuation in fewer than 10% of patients.
-
No clinically significant anticholinergic side effects were observed.
-
The treatment was well tolerated over the full year, with nearly half of the 96 enrolled patients completing 6+ months.
Why It Matters:
Long-term treatment of PAR—especially when rhinorrhea is the dominant symptom—requires safe, targeted options. This study confirms that ipratropium bromide 0.06% offers effective control without significant systemic side effects, even when used continuously for a year.
The Link to Allermi:
Allermi uses ipratropium bromide in select custom nasal spray formulations for patients whose allergy symptoms are dominated by persistent runny nose. This study provides strong validation for Allermi’s approach: using ipratropium as a safe and effective long-term treatment option, particularly in combination with other agents to address broader symptom profiles while minimizing side effects.
For more details, refer to the full study: Long-term treatment of perennial allergic rhinitis with ipratropium bromide nasal spray 0.06%
